Unlike its differential effects on apoptosis induction, obatoclax exhibited autophagy-inhibitory activity in all tested cisplatin-sensitive and -resistant cancer cells, as shown by the increased levels of LC3-II and p62 and elevated numbers of LC3-positive puncta. Here, MAP1LC3A is linked to cancer.